Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMB5U3P)

Drug Name

1,1,1-trifluoroheptadecan-2-one Drug Info

Synonyms

PACOCF3; 1,1,1-trifluoroheptadecan-2-one; 141022-99-3; palmityl trifluoromethyl ketone; Palmitoyl Trifluoromethyl Ketone; CHEMBL99344; 1,1,1-Trifluoro-2-heptadecanone; SR-01000597566; Tocris-1460; AC1L1IOS; AC1Q4I4P; SCHEMBL4653611; Pentadecyl trifluoromethyl ketone; CTK4C2431; C17H31F3O; DTXSID00274441; MAHYXYTYTLCTQD-UHFFFAOYSA-N; MolPort-003-983-793; HMS3649G09; 1,1,1-Trifluoroheptadecen-2-one; HMS3267L18; ZINC8036041; IN1174; BS0141; HSCI1_000022; BDBM50085494; 1974AH; 1,1,1-Trifluoro-2-heptadecanone #; AKOS017343267

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 4670
CAS Number: CAS 141022-99-3
TTD Drug ID: DMB5U3P

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cytosolic phospholipase A2 (GIVA cPLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ZPL521	DMPZE2G	Atopic dermatitis	EA80	Phase 1/2	[2]
EFIPLADIB	DMJ0A5U	Asthma	CA23	Terminated	[3]
1,1,1-Trifluoro-7-phenylheptan-2-one	DMLHVWP	Discovery agent	N.A.	Investigative	[1]
ARACHIDONYL TRIFLUOROMETHYLKETONE	DMHL48F	Discovery agent	N.A.	Investigative	[4]
1,1,1-Trifluoro-8-phenyl-octan-2-one	DMYENI7	Discovery agent	N.A.	Investigative	[1]
AR-C70484XX	DMU3A57	Discovery agent	N.A.	Investigative	[5]
1-Imidazol-1-yl-3-(4-octylphenoxy)propan-2-one	DM3JHVL	Discovery agent	N.A.	Investigative	[5]
AX-006	DMDWCY7	Discovery agent	N.A.	Investigative	[6]
N-(4-Ethoxybutyl)-2-oxohexadecanamide	DM012TN	Discovery agent	N.A.	Investigative	[7]
[3,4''']biflavone	DMHU4NS	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytosolic phospholipase A2 (GIVA cPLA2)	TTT1JVS	PA24A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Synthesis of polyfluoro ketones for selective inhibition of human phospholipase A2 enzymes. J Med Chem. 2008 Dec 25;51(24):8027-37.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Reactions of functionalized sulfonamides: application to lowering the lipophilicity of cytosolic phospholipase A2alpha inhibitors. J Med Chem. 2009 Feb 26;52(4):1156-71.
4	85-kDa cPLA(2) plays a critical role in PPAR-mediated gene transcription in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G586-97.
5	1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem. 2010 Jan 15;18(2):945-52.
6	2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. Bioorg Med Chem. 2009 Jul 1;17(13):4833-43.
7	Structure-activity relationships of natural and non-natural amino acid-based amide and 2-oxoamide inhibitors of human phospholipase A(2) enzymes. Bioorg Med Chem. 2008 Dec 15;16(24):10257-69.
8	Inhibitory effect of synthetic C-C biflavones on various phospholipase A(2)s activity. Bioorg Med Chem. 2007 Nov 15;15(22):7138-43.